What is the current valuation of the Molluscicides Market as of 2024?

The Molluscicides Market was valued at 812.5 USD Million in 2024. Read More

What is the projected market valuation for the Molluscicides Market in 2035?

The market is projected to reach 1466.02 USD Million by 2035. Read More

What is the expected CAGR for the Molluscicides Market during the forecast period 2025 - 2035?

The expected CAGR for the Molluscicides Market during 2025 - 2035 is 5.47%. Read More

Which companies are considered key players in the Molluscicides Market?

Key players in the market include BASF SE, Bayer AG, Syngenta AG, FMC Corporation, and others. Read More

What are the primary applications of molluscicides in the market?

The primary applications include Agriculture, Horticulture, Aquaculture, and Public Health, with Agriculture valued at 300.0 to 550.0 USD Million. Read More

How is the Molluscicides Market segmented by formulation type?

The market is segmented into Granular, Liquid, Pellet, and Emulsifiable Concentrate, with Liquid valued at 325.0 to 590.0 USD Million. Read More

What target organisms are primarily addressed by molluscicides?

The primary target organisms include Snails, Slugs, and Other Gastropods, with Snails valued at 300.0 to 550.0 USD Million. Read More

What modes of action are utilized by molluscicides in the market?

Molluscicides operate through Contact, Ingestion, and Systemic modes, with Ingestion valued at 325.0 to 590.0 USD Million. Read More

What is the regulatory status of molluscicides in the market?

The regulatory status includes Registered, Pending Approval, and Banned, with Registered products valued at 500.0 to 900.0 USD Million. Read More

How does the market performance of molluscicides in 2024 compare to projections for 2035?

The market performance in 2024 at 812.5 USD Million is expected to grow to 1466.02 USD Million by 2035. Read More

Molluscicides Market

Molluscicides Market Size, Share, Industry Trend & Analysis Research Report Information By Type (Chemical Metaldehyde, Methiocarb, Ferric Phosphate, Biological, and Others), By Form (Dry and Liquid), By Crop Type (Vegetables & Fruits, Cereals & Grains, Oilseeds & Pulses, Ornaments and Turf, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Forecast Till 2035

Forecast Period

2025 - 2035

CAGR

5.47%

2024 Market Size

$ 812.5 Million

2035 Market Size

$ 1,466.02 Million

Agriculture ● Updated August 2026 Report ID: MRFR/Agri/3813-HCR | Pages: 110 | Author: Snehal Singh, Varsha More

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Million) | |
  1. 4.1.1 Agriculture | |
  2. 4.1.2 Horticulture | |
  3. 4.1.3 Aquaculture | |
  4. 4.1.4 Public Health |
2. 4.2 Healthcare, BY Formulation Type (USD Million) | |
  1. 4.2.1 Granular | |
  2. 4.2.2 Liquid | |
  3. 4.2.3 Pellet | |
  4. 4.2.4 Emulsifiable Concentrate |
3. 4.3 Healthcare, BY Target Organism (USD Million) | |
  1. 4.3.1 Snails | |
  2. 4.3.2 Slugs | |
  3. 4.3.3 Other Gastropods |
4. 4.4 Healthcare, BY Mode of Action (USD Million) | |
  1. 4.4.1 Contact | |
  2. 4.4.2 Ingestion | |
  3. 4.4.3 Systemic |
5. 4.5 Healthcare, BY Regulatory Status (USD Million) | |
  1. 4.5.1 Registered | |
  2. 4.5.2 Pending Approval | |
  3. 4.5.3 Banned |
6. 4.6 Healthcare, BY Region (USD Million) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 BASF SE (DE) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bayer AG (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Syngenta AG (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 FMC Corporation (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 ADAMA Agricultural Solutions Ltd. (IL) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Nufarm Limited (AU) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sumitomo Chemical Co., Ltd. (JP) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 UPL Limited (IN) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Isagro S.p.A. (IT) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE |
8. 6.5 US MARKET ANALYSIS BY TARGET ORGANISM |
9. 6.6 US MARKET ANALYSIS BY MODE OF ACTION |
10. 6.7 US MARKET ANALYSIS BY REGULATORY STATUS |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET ORGANISM |
14. 6.11 CANADA MARKET ANALYSIS BY MODE OF ACTION |
15. 6.12 CANADA MARKET ANALYSIS BY REGULATORY STATUS |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
19. 6.16 GERMANY MARKET ANALYSIS BY TARGET ORGANISM |
20. 6.17 GERMANY MARKET ANALYSIS BY MODE OF ACTION |
21. 6.18 GERMANY MARKET ANALYSIS BY REGULATORY STATUS |
22. 6.19 UK MARKET ANALYSIS BY APPLICATION |
23. 6.20 UK MARKET ANALYSIS BY FORMULATION TYPE |
24. 6.21 UK MARKET ANALYSIS BY TARGET ORGANISM |
25. 6.22 UK MARKET ANALYSIS BY MODE OF ACTION |
26. 6.23 UK MARKET ANALYSIS BY REGULATORY STATUS |
27. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION |
28. 6.25 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
29. 6.26 FRANCE MARKET ANALYSIS BY TARGET ORGANISM |
30. 6.27 FRANCE MARKET ANALYSIS BY MODE OF ACTION |
31. 6.28 FRANCE MARKET ANALYSIS BY REGULATORY STATUS |
32. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION |
33. 6.30 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
34. 6.31 RUSSIA MARKET ANALYSIS BY TARGET ORGANISM |
35. 6.32 RUSSIA MARKET ANALYSIS BY MODE OF ACTION |
36. 6.33 RUSSIA MARKET ANALYSIS BY REGULATORY STATUS |
37. 6.34 ITALY MARKET ANALYSIS BY APPLICATION |
38. 6.35 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
39. 6.36 ITALY MARKET ANALYSIS BY TARGET ORGANISM |
40. 6.37 ITALY MARKET ANALYSIS BY MODE OF ACTION |
41. 6.38 ITALY MARKET ANALYSIS BY REGULATORY STATUS |
42. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION |
43. 6.40 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
44. 6.41 SPAIN MARKET ANALYSIS BY TARGET ORGANISM |
45. 6.42 SPAIN MARKET ANALYSIS BY MODE OF ACTION |
46. 6.43 SPAIN MARKET ANALYSIS BY REGULATORY STATUS |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TARGET ORGANISM |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY MODE OF ACTION |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY REGULATORY STATUS |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY APPLICATION |
54. 6.51 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
55. 6.52 CHINA MARKET ANALYSIS BY TARGET ORGANISM |
56. 6.53 CHINA MARKET ANALYSIS BY MODE OF ACTION |
57. 6.54 CHINA MARKET ANALYSIS BY REGULATORY STATUS |
58. 6.55 INDIA MARKET ANALYSIS BY APPLICATION |
59. 6.56 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
60. 6.57 INDIA MARKET ANALYSIS BY TARGET ORGANISM |
61. 6.58 INDIA MARKET ANALYSIS BY MODE OF ACTION |
62. 6.59 INDIA MARKET ANALYSIS BY REGULATORY STATUS |
63. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION |
64. 6.61 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
65. 6.62 JAPAN MARKET ANALYSIS BY TARGET ORGANISM |
66. 6.63 JAPAN MARKET ANALYSIS BY MODE OF ACTION |
67. 6.64 JAPAN MARKET ANALYSIS BY REGULATORY STATUS |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TARGET ORGANISM |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY MODE OF ACTION |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY REGULATORY STATUS |
73. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION |
74. 6.71 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TARGET ORGANISM |
76. 6.73 MALAYSIA MARKET ANALYSIS BY MODE OF ACTION |
77. 6.74 MALAYSIA MARKET ANALYSIS BY REGULATORY STATUS |
78. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION |
79. 6.76 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
80. 6.77 THAILAND MARKET ANALYSIS BY TARGET ORGANISM |
81. 6.78 THAILAND MARKET ANALYSIS BY MODE OF ACTION |
82. 6.79 THAILAND MARKET ANALYSIS BY REGULATORY STATUS |
83. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION |
84. 6.81 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
85. 6.82 INDONESIA MARKET ANALYSIS BY TARGET ORGANISM |
86. 6.83 INDONESIA MARKET ANALYSIS BY MODE OF ACTION |
87. 6.84 INDONESIA MARKET ANALYSIS BY REGULATORY STATUS |
88. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION |
89. 6.86 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TARGET ORGANISM |
91. 6.88 REST OF APAC MARKET ANALYSIS BY MODE OF ACTION |
92. 6.89 REST OF APAC MARKET ANALYSIS BY REGULATORY STATUS |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION |
95. 6.92 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
96. 6.93 BRAZIL MARKET ANALYSIS BY TARGET ORGANISM |
97. 6.94 BRAZIL MARKET ANALYSIS BY MODE OF ACTION |
98. 6.95 BRAZIL MARKET ANALYSIS BY REGULATORY STATUS |
99. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION |
100. 6.97 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
101. 6.98 MEXICO MARKET ANALYSIS BY TARGET ORGANISM |
102. 6.99 MEXICO MARKET ANALYSIS BY MODE OF ACTION |
103. 6.100 MEXICO MARKET ANALYSIS BY REGULATORY STATUS |
104. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION |
105. 6.102 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TARGET ORGANISM |
107. 6.104 ARGENTINA MARKET ANALYSIS BY MODE OF ACTION |
108. 6.105 ARGENTINA MARKET ANALYSIS BY REGULATORY STATUS |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET ORGANISM |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODE OF ACTION |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY REGULATORY STATUS |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TARGET ORGANISM |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY MODE OF ACTION |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY REGULATORY STATUS |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TARGET ORGANISM |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY MODE OF ACTION |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY REGULATORY STATUS |
125. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION |
126. 6.123 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TARGET ORGANISM |
128. 6.125 REST OF MEA MARKET ANALYSIS BY MODE OF ACTION |
129. 6.126 REST OF MEA MARKET ANALYSIS BY REGULATORY STATUS |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
138. 6.135 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million) |
140. 6.137 HEALTHCARE, BY TARGET ORGANISM, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TARGET ORGANISM, 2024 TO 2035 (USD Million) |
142. 6.139 HEALTHCARE, BY MODE OF ACTION, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY MODE OF ACTION, 2024 TO 2035 (USD Million) |
144. 6.141 HEALTHCARE, BY REGULATORY STATUS, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY REGULATORY STATUS, 2024 TO 2035 (USD Million) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.2.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.2.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.2.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.3.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.3.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.3.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.3.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.4.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.4.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.4.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.4.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.5.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.5.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.5.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.5.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.6.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.6.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.6.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.6.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.7.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.7.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.7.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.7.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.8.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.8.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.8.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.8.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.9.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.9.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.9.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.9.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.10.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.10.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.10.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.10.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.11.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.11.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.11.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.11.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.12.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.12.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.12.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.12.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.13.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.13.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.13.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.13.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.14.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.14.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.14.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.14.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.15.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.15.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.15.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.15.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.16.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.16.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.16.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.16.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.17.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.17.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.17.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.17.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.18.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.18.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.18.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.18.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.19.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.19.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.19.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.19.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.20.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.20.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.20.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.20.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.21.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.21.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.21.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.21.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.22.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.22.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.22.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.22.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.23.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.23.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.23.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.23.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.24.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.24.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.24.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.24.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.25.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.25.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.25.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.25.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.26.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.26.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.26.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.26.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.27.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.27.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.27.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.27.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.28.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.28.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.28.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.28.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.29.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.29.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.29.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.29.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.30.2 BY FORMULATION TYPE, 2025-2035 (USD Million) | |
  3. 7.30.3 BY TARGET ORGANISM, 2025-2035 (USD Million) | |
  4. 7.30.4 BY MODE OF ACTION, 2025-2035 (USD Million) | |
  5. 7.30.5 BY REGULATORY STATUS, 2025-2035 (USD Million) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Molluscicides Market Segmentation

Molluscicides Market By Application (USD Million, 2025-2035)

Molluscicides Market
Horticulture
Aquaculture
Public Health

Molluscicides Market By Formulation Type (USD Million, 2025-2035)

Granular
Liquid
Pellet
Emulsifiable Concentrate

Molluscicides Market By Target Organism (USD Million, 2025-2035)

Snails
Slugs
Other Gastropods

Molluscicides Market By Mode of Action (USD Million, 2025-2035)

Contact
Ingestion
Systemic

Molluscicides Market By Regulatory Status (USD Million, 2025-2035)

Registered
Pending Approval
Banned

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”